ACT Venture Partners
VC Fund
Amsterdam, The Netherlands
ACT Venture Partners (ACT VP) is a venture capital firm that invests in early-stage deep-tech startups. ACT VP invested in 25 startups in total. ACT's investment philosophy is to identify early-stage ventures and back technical founders with visions and abilities to transform a market or an industry. ACT's target entrepreneurs developbreakthrough products and technologies, establish new market footholds or pursue novel business models.
- Total investments:
- 43
- Last investment:
- Lead investor:
- 67%
- Fund size:
- $22M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries ACT Venture Partners invests in
Stages ACT Venture Partners invests in
Countries ACT Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Seed
- $345k–$3.2M
- Series A
- $2.4M–$9.5M
- Convertible Note
- $1M–$1.4M
Investment Focus
Industry
- Software 6 (14%)
- Artificial Intelligence 6 (14%)
- Biotechnology 4 (9%)
- Manufacturing 4 (9%)
- Enterprise Software 4 (9%)
Stage
- Seed 22 (51%)
- Series A 5 (12%)
- Convertible Note 4 (9%)
- Venture - Series Unknown 3 (7%)
- Pre-Seed 2 (5%)
Country
- Turkey 10 (23%)
- United States 7 (16%)
- United Kingdom 4 (9%)
- Spain 1 (2%)
- Canada 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Duy Louis Tran
Investment Analyst
|
Investment Analyst | Total investments: 0 | Find email | |
Erhan Z. Kilicozlu
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
Gokhan Guner
Managing Partner
|
Managing Partner | Total investments: 6 | Find email | |
Gozde Baloglu
Associate
|
Associate | Total investments: 0 | Find email | |
Gurcan Ozan
Partner
|
Partner | Total investments: 2 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Productive Machines that enable machining companies to be faster to the best part, first time, in an automated way. Unlike competitors who are stuck in a labour intensive iterative cycle to produce parts.Productive Machines have a digital twin of the physics, mechanics, dynamics, distortion and vibration of the machining process for metalcutting, enabling the company to test millions of parameters in simulation to enhance CAM and Gcode to improve productivity and part quality.Productive Machines is a spin out from the UK Advanced Manufacturing Research Centre (AMRC) | $1.7M / Venture - Series Unknown / Sep 21, 2026 | ||
| 3E Nano has developed and is commercializing a low cost, thermally and optically smart, Diamond-Like Carbon (DLC) coating. This nano thin film applied to glass and other transparent media is targeted toward windows, windshields, greenhouses, and solar module manufacturers. | $3.9M / Series A / Jul 16, 2026 | ||
| Cellbricks offers plastic surgery and transplant medicine that rely on artificial materials devoid of physiological functions or immunosuppressive transplants from human and animal sources. It offers the bio-fabrication of human tissue and organs, a widespread medical procedure that enables people to live longer and in better condition. | $8.1M / Seed / Mar 25, 2026 | ||
| Qubitrium develops advanced quantum technologies on the verge of the second quantum revolution. | $2.6M / Seed / Dec 21, 2025 | ||
| Aibuild is a software company with locations in London and Silicon Valley, that is transforming the Additive Manufacturing industry on a global scale. We are on a mission to make manufacturing efficient by accelerating the transition towards factories of the future that are cloud-connected, autonomous and primarily additive. | Dec 16, 2025 | ||
| 3E Nano has developed and is commercializing a low cost, thermally and optically smart, Diamond-Like Carbon (DLC) coating. This nano thin film applied to glass and other transparent media is targeted toward windows, windshields, greenhouses, and solar module manufacturers. | $9.5M / Series A / Oct 14, 2025 | ||
| Qubitrium develops advanced quantum technologies on the verge of the second quantum revolution. | $1.7M / Seed / Sep 05, 2024 | ||
| Meddenovo is at the forefront of AI-driven drug discovery, pioneering a specialized technology platform designed specifically for cyclic peptides. Our innovative approach leverages a unique blend of AI technologies and molecular modeling to significantly enhance the efficiency and success rates of drug development processes. Cyclic peptidesrepresent a groundbreaking class of compounds in pharmaceutical research. These molecules combine the best attributes of small molecules and large biologics, offering exceptional binding affinities, stability, and specificity. At Meddenovo, we are leaders in harnessing the potential of cyclic peptides, developing tailored solutions that push the boundaries of traditional drug discovery. Beyond small organic molecules, our expertise extends to peptide-based medicines and metal chelators, giving us a competitive edge in novel drug research and development. We excel in creating unique chemical spaces tailored to your needs and provide custom computational solutions for predicting drug resistance, elucidating biochemical reaction mechanisms, and conducting metal affinity analysis. At Meddenovo, we are dedicated to precision and reliability in drug discovery. Our approach reduces failure rates and improves outcomes, accelerating the journey from research to market. Our mission is to empower scientists worldwide with advanced, user-friendly AI tools, democratizing access to cutting-edge drug discovery technologies. | $1.1M / Pre-Seed / Jul 31, 2024 | ||
| Nextmol is a Barcelona-based startup specialized in computational chemistry. It develops a software platform to accelerate the design of new chemicals through molecular modeling and artificial intelligence for a more efficient R&D. Nextmol shortens the path to chemical innovation over the traditional lab approach thanks to its ability toperform unlimited testing via computations. Furthermore, computations provide key insights about the physico-chemical behavior of the candidate molecules. Nextmol is a spin-off company of the Barcelona Supercomputing Center, one of the largest supercomputing facilities in Europe. | Venture - Series Unknown / May 27, 2024 | ||
| Cellbricks offers plastic surgery and transplant medicine that rely on artificial materials devoid of physiological functions or immunosuppressive transplants from human and animal sources. It offers the bio-fabrication of human tissue and organs, a widespread medical procedure that enables people to live longer and in better condition. | Venture - Series Unknown / Apr 23, 2024 | ||
| See all 43 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does ACT Venture Partners invest in?
ACT Venture Partners invests primarily in Software, Artificial Intelligence and Biotechnology startups, most often at Seed and Series A stage. Most of the 43 investments tracked by Shizune back companies in Turkey. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is ACT Venture Partners's check size?
ACT Venture Partners typically joins rounds of $345k–$3.2M at Seed, $2.4M–$9.5M at Series A and $1M–$1.4M at Convertible Note. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ACT Venture Partners participates in.
How do I contact ACT Venture Partners?
Public channels for ACT Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ACT Venture Partners?
The team at ACT Venture Partners includes Duy Louis Tran (Investment Analyst), Erhan Z. Kilicozlu (Managing Partner) and Gokhan Guner (Managing Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
